Abstract
The discovery of the orexin system represents the single major progress in the sleep field of the last three to four decades. The two orexin peptides and their two receptors play a major role in arousal and sleep/wake cycles. Defects in the orexin system lead to narcolepsy with cataplexy in humans and dogs and can be experimentally reproduced in rodents. At least six orexin receptor antagonists have reached Phase II or Phase III clinical trials in insomnia, five of which are dual orexin receptor antagonists (DORAs) that target both OX1 and OX2 receptors (OX2Rs). All clinically tested DORAs induce and maintain sleep: suvorexant, recently registered in the USA and Japan for insomnia, represents the first hypnotic principle that acts in a completely different manner from the current standard medications. It is clear, however, that in the clinic, all DORAs promote sleep primarily by increasing rapid eye movement (REM) and are almost devoid of effects on slow-wave (SWS) sleep. At present, there is no consensus on whether the sole promotion of REM sleep has a negative impact in patients suffering from insomnia. However, sleep onset REM (SOREM), which has been documented with DORAs, is clearly an undesirable effect, especially for narcoleptic patients and also in fragile populations (e.g. elderly patients) where REM-associated loss of muscle tone may promote an elevated risk of falls. Debate thus remains as to the ideal orexin agent to achieve a balanced increase in REM and non-rapid eye movement (NREM) sleep. Here, we review the evidence that an OX2R antagonist should be at least equivalent, or perhaps superior, to a DORA for the treatment of insomnia. An OX2R antagonist may produce more balanced sleep than a DORA. Rodent sleep experiments show that the OX2R is the primary target of orexin receptor antagonists in sleep modulation. Furthermore, an OX2R antagonist should, in theory, have a lower narcoleptic/cataplexic potential. In the clinic, the situation remains equivocal, since OX2R antagonists are in early stages: MK-1064 has completed Phase I, and MIN202 is currently in clinical Phase II/III trials. However, data from insomnia patients have not yet been released. Promotional material suggests that balanced sleep is indeed induced by MIN-202, whereas in volunteers MK-1064 has been reported to act similarly to DORAs.
This is a preview of subscription content, log in via an institution.
Abbreviations
- 2-SORA:
-
Selective orexin 2 receptor antagonist
- BNST:
-
Bed nucleus of the stria terminalis
- CHMP:
-
Committee for Medicinal Products for Human Use
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
- DMH:
-
Dorsomedial hypothalamic nuclei
- DORA:
-
Dual orexin receptor antagonist
- DOX:
-
Doxycycline
- DR:
-
Dorsal raphe
- DREADDs:
-
Designer receptors exclusively activated by designer drugs
- DREM:
-
Direct transitions between wake and REM sleep
- DSM-IV/DSM-V:
-
Diagnostic and Statistical Manual of Mental Disorders Fourth/Fifth edition
- DTA mice:
-
Mice in which selective orexin neuron loss is engineered by inducible expression of diphtheria toxin A
- EDS:
-
Excessive daytime sleepiness
- EMA:
-
European Medicines Agency
- FDA:
-
US Food and Drug Administration
- GABAAR:
-
Gamma-aminobutyric acid A receptor
- HCRT:
-
Hypocretin
- ICV:
-
Intracerebroventricular
- KO:
-
Knockout
- LC:
-
Locus coeruleus
- LDT:
-
Laterodorsal tegmental nucleus
- LH:
-
Lateral hypothalamus
- LPT:
-
Lateral pontine tegmentum
- MnPO:
-
Median preoptic nucleus
- NREM:
-
Non-rapid eye movement sleep
- OX:
-
Orexin
- OXR:
-
Orexin receptor
- OX1R:
-
Orexin 1 receptor
- OX2R:
-
Orexin 2 receptor
- PB:
-
Parabrachial nucleus
- PC:
-
Precoeruleus
- PPT:
-
Pedunculopontine tegmental area
- PSG:
-
Polysomnography
- REM:
-
Rapid eye movement sleep
- SCN:
-
Suprachiasmatic nucleus
- SORA:
-
Selective orexin receptor antagonist
- SOREM:
-
Sleep onset REM
- SLD:
-
Sublaterodorsal nucleus
- SWS:
-
Slow-wave sleep
- TMN:
-
Tuberomammillary nucleus
- TST:
-
Total sleep time
- vlPAG:
-
Ventrolateral periaqueductal grey
- VLPO:
-
Ventrolateral preoptic area
- vPAG:
-
Ventral periaqueductal grey
- VTA:
-
Ventral tegmental area
- WASO:
-
Wake after sleep onset
- WT:
-
Wild type
- Z drugs:
-
Non-benzodiazepine site GABAA receptor positive allosteric modulators; the current market-leading hypnotics (zopiclone, zolpidem, eszopiclone, zaleplon)
- ZT:
-
Zeitgeber time (ZT0 and ZT24 = lights on, ZT12 = lights off)
References
APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, VA
Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13:879–893
Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322
FDA Drug Safety Communication (10 Jan 2013) Safety announcement: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). U.S. food and drug administration. http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm
FDA Drug Safety Communication (14 May 2013) FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. U.S. food and drug administration. http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm
Randall S, Roehrs T, Harris E, Maan R, Roth T (2010) Chronic use of zolpidem is not associated with loss of efficacy. Sleep 33 Supplement: Abstract 0660, A221.
Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26:1088–1095
Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D (2016) Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 79:136–148
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D (2012) Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79:2265–2274
Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ (2014) Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 37:1609–1619
Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ (2014) Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:461–471
Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ (2016) Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase-3 data. Sleep Med 19:93–100. doi:10.1016/j.sleep.2015.10.007
Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li XD, Ma JS, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM (2013) Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36:259–267
Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 17(4):263–272. doi:10.1016/j.smrv.2012.08.001
Ferracioli-Oda E, Qawasmi A, Bloch MH (2013) Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 8(5):e63773
Kuriyama A, Honda M, Hayashino Y (2014) Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 15:385–392
De Lecea L, Kilduff TS, Peyron C, Gao XB, Foye PE, Danielson PE, Fukuhara C, Battenberg ELF, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95:322–327
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, Goto K (1999) Structure and function of human prepro-orexin gene. J Biol Chem 274:17771–17776
Sutcliffe JG, de Lecea L (2002) The hypocretins: setting the arousal threshold. Nat Rev Neurosci 3:339–349
Burgess CR, Scammell TE (2012) Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 32:12305–12311
Scammell TE, Willie JT, Guilleminault C, Siegel JM, Int Working Grp Rodent Models N (2009) A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32:111–116
Bassetti CL, Mathis J, Gugger M, Sturzenegger C, Mignot E, Radanov B (2001) Idiopathic hypersomnia and narcolepsy without cataplexy: a multimodal diagnostic approach in 20 patients including CSF orexin levels. Neurology 56:A8–A8
Baumann CR, Mignot E, Lammers GJ, Overeem S, Arnulf I, Rye D, Dauvilliers Y, Honda M, Owens JA, Plazzi G, Scammell TE (2014) Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37:1035–1042
Beuckmann CT, Sinton CM, Williams SC, Richardson JA, Hammer RE, Sakurai T, Yanagisawa M (2004) Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 24:4469–4477
Bourgin P, Zeitzer JM, Mignot E (2008) CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 7:649–662
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong YM, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345–354
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin XY, Qiu XH, de Jong PJ, Nishino S, Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365–376
Mignot E, Chen W, Black J (2003) On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 26:646–649
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, Mignot E (2001) Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50:381–388
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474
Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu CB, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13:150–155
Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M (2011) Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett 21:5562–5567
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang CY, Roller S, Cabalu TD, Cui DH, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ (2010) Discovery of the dual orexin receptor antagonist (7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl 5-met hyl-2-(2H-1,2,3-triazol-2-yl) phenyl methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320–5332
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui DH, Coleman PJ, Renger JJ (2011) Promotion of sleep by suvorexant – a novel dual orexin receptor antagonist. J Neurogenet 25:52–61
Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui DH, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ (2012) Discovery of (2R,5R)-5-{ (5-Fluoropyridin-2-yl)oxy methyl}-2-methylpiperidin-1-yl 5 -methyl-2-(pyrimidin-2-yl)phenyl methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 7:415–424
Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui DH, Coleman PJ, Renger JJ (2012) Pharmacological characterization of MK-6096-A dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978–987
Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M (2015) Discovery of (1R,2S)-2-{ (2,4-Dimethylpyrimidin-5-yl)oxy methy1}-2-(3-fluorophenyl)-N -(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist. J Med Chem 58:4648–4664
Actelion/GlaxoSmithKline. Actelion and GSK discontinue clinical development of almorexant. http://www.actelion.com/en/investors/media-releases/index.page?newsId=1483135
Farkas R (2013) Suvorexant safety and efficacy. U.S. food and drug administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM354215.pdf
FDA. Highlights of prescribing information: Belsomra® (suvorexant) tablets (2014) http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf
Suvorexant. Advisory Committee Briefing Document (2013) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM352970.pdf
Jacobson LH, Callander GE, Hoyer D (2014) Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 7:711–730
Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA, Collaborators CGTP (2015) The concise guide to pharmacology 2015/16: G protein coupled receptors. Br J Pharmacol 172(24):5744–5869
Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ (2012) International union of basic and clinical pharmacology. LXXXVI. orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 64:389–420
Alvarez CE, Sutcliffe JG (2002) Hypocretin is an early member of the incretin gene family. Neurosci Lett 324:169–172
Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996–10015
Abe T, Mieda M, Yanagisawa M, Tanaka K, Sakurai T (2009) Both ox1r and ox2r orexin receptors mediate efferent signals of orexin neurons in eliciting food-anticipatory activity. J Physiol Sci 59:286–286
Lebold TP, Bonaventure P, Shireman BT (2013) Selective orexin receptor antagonists. Bioorg Med Chem Lett 23:4761–4769
Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, Merlo-Pich E, Di Fabio R, Corsi M (2012) Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37:1999–2011
Bonnavion P, de Lecea L (2010) Hypocretins in the control of sleep and wakefulness. Curr Neurol Neurosci Rep 10:174–179
Willie JT, Chemelli RM, Sinton CM, Yanagisawa M (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 24:429–458
Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K (1999) Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849:248–252
Alam MN, Gong H, Alam T, Jaganath R, McGinty D, Szymusiak R (2002) Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area. J Physiol 538:619–631
de Lecea L, Carter ME, Adamantidis A (2012) Shining light on wakefulness and arousal. Biol Psychiatry 71:1046–1052
Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171–181
Liblau RS, Vassalli A, Seifinejad A, Tafti M (2015) Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 14:318–328
Scammell TE (2015) Narcolepsy. N Engl J Med 373:2654–2662
Thompson MD, Comings DE, Abu-Ghazalah R, Jereseh Y, Lin L, Wade J, Sakurai T, Tokita S, Yoshida T, Tanaka H, Yanagisawa M, Burnham WM, Moldofsky H (2004) Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette’s syndrome comorbidity. Am J Med Genet B Neuropsychiatr Genet 129B:69–75
Saper CB, Chou TC, Scammell TE (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24:726–731
Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE (2010) Sleep state switching. Neuron 68:1023–1042
de Lecea L, Heurta R (2014) Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol 5:16. doi:10.3389/fphar2014.00016
Luppi PH, Peyron C, Fort P (2016) Not a single but multiple populations of GABAergic neurons control sleep. Sleep Med Rev. doi:10.1016/j.smrv.2016.03.002
Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM (2014) Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease. J Exp Med 211:2487–2496
Liguori C (2016) Orexin and Alzheimer’s disease. Curr Top Behav Neurosci. doi:10.1007/7854_2016_50
Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE (2004) Behavioral state instability in orexin knock-out mice. J Neurosci 24:6291–6300
Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 101:4649–4654
Mieda M, Willie JT, Sakurai T (2005) Rescue of narcoleptic orexin neuron-ablated mice by ectopic overexpression of orexin peptides. In: Nishino S, Sakurai T (eds) Orexin/Hypocretin system: physiology and pathophysiology, Contemporary clinical neuroscience. Humana Press, Totowa, pp 359–366
Tabuchi S, Tsunematsu T, Black SW, Tominaga M, Maruyama M, Takagi K, Minokoshi Y, Sakurai T, Kilduff TS, Yamanaka A (2014) Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34:6495–6509
Adamantidis A, Carter ME, de Lecea L, Shaw P, Tafti M, Thorpy M (2013) Optogenetic control of arousal neurons. In: Shaw P, Tafti M, Thorpy M (eds) Genetic basis of sleep and sleep disorders. Cambridge University Press, Cambridge, pp 66–72
Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, De Lecea L (2007) Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:420–U429
Carter ME, Yizhar O, Chikahisa S, Nguyen H, Adamantidis A, Nishino S, Deisseroth K, de Lecea L (2010) Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat Neurosci 13:1526–U1117
Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A (2011) Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 31:10529–10539
Espana RA, McCormack SL, Mochizuki T, Scammell TE (2007) Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30:1417–1425
Mochizuki T, Arrigoni E, Marcus JN, Clark EL, Yamamoto M, Honer M, Borroni E, Lowell BB, Elmquist JK, Scammell TE (2011) Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci U S A 108:4471–4476
Willie JT, Chemelli RM, Sinston CM, Tokita H, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M (2003) Distinct narcolepsy syndromes in orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38:715–730
Adamantidis A, de Lecea L (2008) Physiological arousal: a role for hypothalamic systems. Cell Mol Life Sci 65:1475–1488
Adamantidis A, de Lecea L (2008) Sleep and metabolism: shared circuits, new connections. Trends Endocrinol Metab 19:362–370
Adamantidis A, de Lecea L (2009) The hypocretins as sensors for metabolism and arousal. J Physiol 587:33–40
Sakurai T (2014) The role of orexin in motivated behaviours. Nat Rev Neurosci 15:719–731
Hoyer D, Jacobson LH (2013) Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides 47:477–488
Tafti M (2007) Reply to ‘promotion of sleep by targeting the orexin system in rats, dogs and humans’. Nat Med 13:525–526
Hoyer D (2007) RNA interference for studying the molecular basis of neuropsychiatric disorders. Curr Opin Drug Discov Devel 10:122–129
Urban DJ, Roth BL (2015) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol 55:399–417
Branch AF, Navidi W, Tabuchi S, Terao A, Yamanaka A, Scammell TE, Diniz Behn C (2016) Progressive loss of the orexin neurons reveals dual effects on wakefulness. Sleep 39:369–377
Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR, Sutcliffe JG, Henriksen SJ, de Lecea L (2000) Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 20:7760–7765
Chen LC, McKenna JT, Bolortuya Y, Brown RE, McCarley RW (2013) Knockdown of orexin type 2 receptor in the lateral pontomesencephalic tegmentum of rats increases REM sleep. Eur J Neurosci 37:957–963
Chen LC, McKenna JT, Bolortuya Y, Winston S, Thakkar MM, Basheer R, Brown RE, McCarley RW (2010) Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. Eur J Neurosci 32:1528–1536
Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, Corsi M, Bifone A (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 6(1):e16406. doi:10.1371/journal.pone.0016406
Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T (2011) Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J Neurosci 31:6518–6526
Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, Bonaventure P, Yun S, Li X, Lord B, Dvorak CA, Carruthers NI, Lovenberg TW (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 330:142–151
Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW (2014) Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 8:28. doi:10.3389/fnins.2014.00028
Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H-3 receptor improves wakefulness in narcolepsy: studies in orexin(-/-) mice and patients. Neurobiol Dis 30:74–83
Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Goder R, Aldenhoff JB, Hinze-Selch D (2011) Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 12:941–946
Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D (2008) Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin-1). Brain 131:2734–2741
Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Goder R, Baier PC (2014) The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 262:8–13
Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, Gouda H, Kumagai H, Fujii H, Yanagisawa M, Nagase H (2015) Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem 58:7931–7937
Carter ME, de Lecea L, Adamantidis A (2013) Functional wiring of hypocretin and LC-NE neurons: implications for arousal. Front Behav Neurosci 7:43. doi:10.3389/fnbeh.2013.00043
Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ (2013) Quantitative electroencephalography within sleep/wake states differentiates GABA(A) modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 38:2401–2408
Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ (2014) Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators. BMC Neurosci 15:109. doi:10.1186/1471-2202-15-109
Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ (2014) Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 8:182
Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ (2013) Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 7:254. doi:10.3389/fnins.2013.00254
Tye SJ, Uslaner JM, Eddins DM, Savitz AT, Fox SV, Cannon CE, Binns J, Garson SL, Stevens J, Yao L, Hodgson R, Brunner J, McDonald TP, Bowlby MR, Tannenbaum PL, Kuduk SD, Gotter AL, Winrow CJ, Renger JJ (2012) Sleep-promoting doses of diazepam, eszopiclone and zolpidem disrupt Rhesus macaque memory and attention as compared to DORA-22, a dual orexin receptor antagonist. Society for Neuroscience Annual Meeting, New Orleans, USA, Abstract 921.20/EEE48
Uslaner JM, Tye SJ, Eddins DM, Wang XH, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao LH, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, McDonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ (2013) Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 5(179):179ra44. doi:10.1126/scitranslmed.3005213
Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck F (2011) Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-alpha 1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 36:848–856
Coleman PJ, Cox CD, Roecker AJ (2011) Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Curr Top Med Chem 11:696–725
Scammell TE, Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243–266
Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R (2012) Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 26:1058–1070
Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (2012) Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37:1224–1233
Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (2012) The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35:1097–1104
Mang GM, Durst T, Burki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE (2012) The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35:1625–1635
Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD (2015) Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J Psychopharmacol 29:1159–1169
Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS (2013) Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 36:325–336
Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ (2014) Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 24:4884–4890
Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ (2015) Identification of MK-8133: an orexin-2 selective receptor antagonist with favorable development properties. Bioorg Med Chem Lett 25:2488–2492
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C (2015) Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther 354:471–482
Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ (2016) Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Sci Rep 6:27147. doi:10.1038/srep27147
Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D (2013) Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 56:7590–7607
Hoyer D, Durst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE (2013) Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 7:235. doi:10.3389/fnins.2013.00235
Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman BT, Young LK, Yun S (2015) Novel octahydropyrrolo 3,4-c pyrroles are selective orexin-2 antagonists: SAR leading to a clinical candidate. J Med Chem 58:5620–5636
Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C (2015) A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther 352(3):590–601
McAtee LC, Sutton SW, Rudolph DA, Li X, Aluisio LE, Phuong VK, Dvorak CA, Lovenberg TW, Carruthers NI, Jones TK (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 14:4225–4229
Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui DH, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ (2014) Discovery of 5 “-Chloro-N-(5,6-dimethoxypyridin-2-yl)methyl-2,2′:5′,3 ″-terpyridine-3′-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 9:311–322
Mercer SP, Roecker AJ, Garson S, Reiss DR, Meacham Harrell C, Murphy KL, Bruno JG, Bednar RA, Lemaire W, Cui D, Cabalu TD, Tang C, Prueksaritanont T, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ (2013) Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorg Med Chem Lett 23:6620–6624
Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ (2015) Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorg Med Chem Lett 25:4992–4999
Fujimoto T, Kunitomo J, Tomata Y, Nishiyama K, Nakashima M, Hirozane M, Yoshikubo S, Hirai K, Marui S (2011) Discovery of potent, selective, orally active benzoxazepine-based orexin-2 receptor antagonists. Bioorg Med Chem Lett 21:6414–6416
Etori K, Saito YC, Tsujino N, Sakurai T (2014) Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 8:8. doi:10.3389/fnins.2014.00008
Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C (2015) Substituted pyrrolidin-2-ones: centrally acting orexin receptor antagonists promoting sleep. Part 2. Bioorg Med Chem Lett 25:1884–1891
Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E (2012) Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 7(7):e39131. doi:10.1371/journal.pone.0039131
Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, Iwaasa H, Hata M, Fukami T, Kanatani A, Yamada K (2003) N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 13:4497–4499
Moore MW, Akladious A, Hu Y, Azzam S, Feng P, Strohl KP (2014) Effects of orexin 2 receptor activation on apnea in the C57BL/6J mouse. Respir Physiol Neurobiol 200:118–125
Kummangal BA, Kumar D, Mallick HN (2013) Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behav Brain Res 237:59–62
Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ (2015) Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorg Med Chem Lett 25:444–450
Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM (2014) LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 8:5. doi:10.3389/fnins.2014.00005
Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM (2014) Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci 8:33. doi:10.3389/fnins.2014.00033
Brodnik ZD, Bernstein DL, Prince CD, España RA (2015) Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res 291:377–384
Boss C, Roch C (2015) Recent trends in orexin research-2010 to 2015. Bioorg Med Chem Lett 25:2875–2887
Hoever P, de Haas S, Dorffner G, Chiossi E, van Gerven J, Dingemanse J (2012) Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol 26:1071–1080
Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 87:593–600
Hoever P, Dorffner G, Benes H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Hogl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J (2012) Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 91:975–985
Toth LA, Bhargava P (2013) Animal models of sleep disorders. Comp Med 63:91–10
Boss C, Brisbare-Roch C, Steiner MA, Treiber A, Dietrich H, Jenck F, von Raumer M, Sifferlen T, Brotschi C, Heidmann B, Williams JT, Aissaoui H, Siegrist R, Gatfield J (2014) Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist. ChemMedChem 9:2486–2496
Suzuki R, Nozawa D, Futamura A, Nishikawa-Shimono R, Abe M, Hattori N, Ohta H, Araki Y, Kambe D, Ohmichi M, Tokura S, Aoki T, Ohtake N, Kawamoto H (2015) Discovery and in vitro and in vivo profiles of N-ethyl-N- 2- 3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl ethyl -2-(2H-1,2, 3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist. Bioorganic & Medicinal Chemistry 23:1260–1275
Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D (2013) Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 7:230. doi:10.3389/fnins.2013.00230
Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, Moreau JL (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156:1326–1341
Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F (2009) Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX(1))/orexin 2 receptor (OX(2)) antagonist: comparison with selective OX(1) and OX(2) antagonists. Mol Pharmacol 76:618–631
Smith MI, Piper DC, Duxon MS, Upton N (2003) Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett 341:256–258
Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (2013) Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8:898–903
Dauvilliers Y, Jennum P, Plazzi G (2013) Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med 14:775–781
Minerva Neurosciences Inc (2015) Press release 21 Jan 2015: ‘Minerva neuroscience reports positive phase 1 data with MIN-202, selective orexin-2 antagonist for treatment of sleep disorders including primary and comorbid insomnia’. http://ir.minervaneurosciences.com/releases.cfm?ReleaseID=892355
Minerva Neurosciences Inc (2016) Press release 11 Jan 2016: ‘Minerva neurosciences announces favorable top line results from MIN-202 phase 2A clinical trial in insomnia disorder’. http://ir.minervaneurosciences.com/releasedetail.cfm?ReleaseID=949714
Minerva Neurosciences Inc (2016) Press release 1 Feb 2016: ‘Minerva neurosciences announces top line data from MIN-202 phase I clinical study in Japanese patients’. http://ir.minervaneurosciences.com/releasedetail.cfm?ReleaseID=952576
Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers ACM, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J (2015) On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep 38:1803–1813
Riemann D, Spiegelhalder K, Nissen C, Hirscher V, Baglioni C, Feige B (2012) REM sleep instability – a new pathway for insomnia? Pharmacopsychiatry 45:167–176
Staner L, Van Veeren C, Stefos G, Hubain PP, Linkowski P, Mendlewicz J (1998) Neuroendocrine and clinical characteristics of major depressed patients exhibiting sleep-onset REM. Biol Psychiatry 43:817–821
Stefos G, Staner L, Kerkhofs M, Hubain P, Mendlewicz J, Linkowski P (1998) Shortened REM latency as a psychobiological marker for psychotic depression? An age-, gender-, and polarity-controlled study. Biol Psychiatry 44:1314–1320
Park H, Satoh H, Miki A, Urushihara H, Sawada Y (2015) Medications associated with falls in older people: systematic review of publications from a recent 5-year period. Eur J Clin Pharmacol 71:1429–1440
Tamiya H, Yasunaga H, Matusi H, Fushimi K, Ogawa S, Akishita M (2015) Hypnotics and the occurrence of bone fractures in hospitalized dementia patients: a matched case-control study using a national inpatient database. PLoS One 10(6):e0129366. doi:10.1371/journal.pone.0129366
https://clinicaltrials.gov/show/NCT01995838: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive randomization design, dose response study of the efficacy of E2006 in adults and elderly subjects with chronic insomnia
Hoch M, van Gorsel H, van Gerven J, Dingemanse J (2014) Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. J Clin Pharmacol 54:979–986
MSD Corporation (2013) Suvorexant advisory committee briefing document. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM352970.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Jacobson, L.H., Chen, S., Mir, S., Hoyer, D. (2016). Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence, A.J., de Lecea, L. (eds) Behavioral Neuroscience of Orexin/Hypocretin. Current Topics in Behavioral Neurosciences, vol 33. Springer, Cham. https://doi.org/10.1007/7854_2016_47
Download citation
DOI: https://doi.org/10.1007/7854_2016_47
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-57534-6
Online ISBN: 978-3-319-57535-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)